ANIK
Anika Therapeutics, Inc.
Medical - Devices
Market Cap$198M
5Y Perf.-55.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ANIK vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1690.08T
5Y Perf.-59.3%
ANIK vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ANIK | DBVT |
|---|---|---|
| Industry | Medical - Devices | Biotechnology |
| Market Cap | $198M | $1690.08T |
| Revenue (TTM) | $116M | $0.00 |
| Net Income (TTM) | $-11M | $-168M |
| Gross Margin | 58.6% | — |
| Operating Margin | -10.5% | — |
| Total Debt | $24M | $22M |
| Cash & Equiv. | $57M | $194M |
ANIK vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ANIK
DBVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Anika Therapeutics,… (ANIK) | 100 | 44.1 | -55.9% |
| DBV Technologies S.… (DBVT) | 100 | 40.7 | -59.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ANIK vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ANIK leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. DBV Technologies S.A. is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
ANIK
Anika Therapeutics, Inc.
The Income Pick
ANIK carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.10
- Rev growth -5.9%, EPS growth 80.2%, 3Y rev CAGR -0.3%
- -66.7% 10Y total return vs DBVT's -87.1%
Best for: income & stability and growth exposure
DBVT
DBV Technologies S.A.
The Quality Compounder
DBVT is the clearest fit if your priority is quality and momentum.
- 0.3% margin vs ANIK's -9.5%
- +100.5% vs ANIK's +0.2%
Best for: quality and momentum
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ANIK | -5.9% revenue growth vs DBVT's -100.0% |
| Quality / Margins | DBVT | 0.3% margin vs ANIK's -9.5% |
| Stability / Safety | ANIK | Beta 1.10 vs DBVT's 1.26 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | DBVT | +100.5% vs ANIK's +0.2% |
| Efficiency (ROA) | ANIK | -5.9% ROA vs DBVT's -89.0% |
ANIK vs DBVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2023
Segment breakdown not available.
ANIK vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLANIKLAGGINGDBVT
DBVTDBV Technologies S.A.
1leads
ANIKAnika Therapeutics, I…
2leads
6 Total Categories
CATEGORYLEADERvs DBVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DBVT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ANIK4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
ANIK2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ANIK and DBVT operate at a comparable scale, with $116M and $0 in trailing revenue.
| Metric | ANIKAnika Therapeutic… | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $116M | $0 |
| EBITDAEarnings before interest/tax | -$7M | -$112M |
| Net IncomeAfter-tax profit | -$11M | -$168M |
| Free Cash FlowCash after capex | $1M | -$151M |
| Gross MarginGross profit ÷ Revenue | +58.6% | — |
| Operating MarginEBIT ÷ Revenue | -10.5% | — |
| Net MarginNet income ÷ Revenue | -9.5% | — |
| FCF MarginFCF ÷ Revenue | +0.9% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +13.2% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -8.8% | +91.5% |
DBVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — ANIK and DBVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ANIKAnika Therapeutic… | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $198M | $1690.08T |
| Enterprise ValueMkt cap + debt − cash | $165M | $1690.08T |
| Trailing P/EPrice ÷ TTM EPS | -19.43x | -0.75x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 1.75x | — |
| Price / BookPrice ÷ Book value/share | 1.48x | 0.65x |
| Price / FCFMarket cap ÷ FCF | 45.38x | — |
Evenly matched — ANIK and DBVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
ANIK leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
ANIK delivers a -7.7% return on equity — every $100 of shareholder capital generates $-8 in annual profit, vs $-130 for DBVT. DBVT carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to ANIK's 0.17x. On the Piotroski fundamental quality scale (0–9), ANIK scores 6/9 vs DBVT's 4/9, reflecting solid financial health.
| Metric | ANIKAnika Therapeutic… | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | -7.7% | -130.2% |
| ROA (TTM)Return on assets | -5.9% | -89.0% |
| ROICReturn on invested capital | -7.1% | — |
| ROCEReturn on capital employed | -6.4% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 |
| Debt / EquityFinancial leverage | 0.17x | 0.13x |
| Net DebtTotal debt minus cash | -$33M | -$172M |
| Cash & Equiv.Liquid assets | $57M | $194M |
| Total DebtShort + long-term debt | $24M | $22M |
| Interest CoverageEBIT ÷ Interest expense | — | -189.82x |
ANIK leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — ANIK and DBVT each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ANIK five years ago would be worth $3,559 today (with dividends reinvested), compared to $3,172 for DBVT. Over the past 12 months, DBVT leads with a +100.5% total return vs ANIK's +0.2%. The 3-year compound annual growth rate (CAGR) favors DBVT at 5.7% vs ANIK's -17.2% — a key indicator of consistent wealth creation.
| Metric | ANIKAnika Therapeutic… | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | +58.0% | +3.6% |
| 1-Year ReturnPast 12 months | +0.2% | +100.5% |
| 3-Year ReturnCumulative with dividends | -43.1% | +18.1% |
| 5-Year ReturnCumulative with dividends | -64.4% | -68.3% |
| 10-Year ReturnCumulative with dividends | -66.7% | -87.1% |
| CAGR (3Y)Annualised 3-year return | -17.2% | +5.7% |
Evenly matched — ANIK and DBVT each lead in 3 of 6 comparable metrics.
Risk & Volatility
ANIK leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ANIK is the less volatile stock with a 1.10 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ANIK currently trades 90.9% from its 52-week high vs DBVT's 75.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ANIKAnika Therapeutic… | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.10x | 1.26x |
| 52-Week HighHighest price in past year | $16.24 | $26.18 |
| 52-Week LowLowest price in past year | $7.87 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +90.9% | +75.3% |
| RSI (14)Momentum oscillator 0–100 | 53.5 | 47.4 |
| Avg Volume (50D)Average daily shares traded | 131K | 252K |
ANIK leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ANIK as "Buy" and DBVT as "Buy".
| Metric | ANIKAnika Therapeutic… | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | $46.33 |
| # AnalystsCovering analysts | 6 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +4.8% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ANIK leads in 2 of 6 categories (Profitability & Efficiency, Risk & Volatility). DBVT leads in 1 (Income & Cash Flow). 2 tied.
Best OverallAnika Therapeutics, Inc. (ANIK)Leads 2 of 6 categories
Loading custom metrics...
ANIK vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ANIK or DBVT a better buy right now?
Analysts rate Anika Therapeutics, Inc.
(ANIK) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ANIK or DBVT?
Over the past 5 years, Anika Therapeutics, Inc.
(ANIK) delivered a total return of -64. 4%, compared to -68. 3% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: ANIK returned -66. 7% versus DBVT's -87. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ANIK or DBVT?
By beta (market sensitivity over 5 years), Anika Therapeutics, Inc.
(ANIK) is the lower-risk stock at 1. 10β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 14% more volatile than ANIK relative to the S&P 500. On balance sheet safety, DBV Technologies S. A. (DBVT) carries a lower debt/equity ratio of 13% versus 17% for Anika Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — ANIK or DBVT?
On earnings-per-share growth, the picture is similar: Anika Therapeutics, Inc.
grew EPS 80. 2% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ANIK or DBVT?
DBV Technologies S.
A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -9. 6% for Anika Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus -9. 8% for ANIK. At the gross margin level — before operating expenses — ANIK leads at 56. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ANIK or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ANIK or DBVT better for a retirement portfolio?
For long-horizon retirement investors, Anika Therapeutics, Inc.
(ANIK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 10)). Both have compounded well over 10 years (ANIK: -66. 7%, DBVT: -87. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ANIK and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.